HHC
SGNT

Hutchin Hill Capital’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Hutchin Hill Capital’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-17,600
Closed -$411K – 833
2014
Q1 		$411K Buy
+17,600
New +$385K 0.02% 494
2013
Q4 		– Sell
-12,700
Closed -$259K – 704
2013
Q3 		$259K Buy
+12,700
New +$283K 0.02% 405

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

Hutchin Hill Capital's SGNT Position: Q2 2014 in Review

Hutchin Hill Capital sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2014, closing a stake of 17,600 shares — an estimated $411K sold.

Hutchin Hill Capital first reported a position in SGNT in Q3 2013 and held it in 2 quarters. The position peaked at $411K in Q1 2014. 104 funds tracked by Wall St. Rank hold SGNT as of Q2 2014.

  • Hutchin Hill Capital reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Hutchin Hill Capital sold 17,600 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2014, an estimated $411K.
  • Hutchin Hill Capital first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 2 quarters.
  • Hutchin Hill Capital's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $411K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2014.

Based on Hutchin Hill Capital's 13F filing for Q2 2014, filed 14 Aug 2014.